STRIANT® (testosterone buccal system) was approved by the FDA in June 2003 for a deficiency or absence of endogenous testosterone associated with hypogonadism in men. This novel product uses our buccal delivery technology to deliver testosterone across the buccal mucosa (the lining of the cheek and gum) and into the bloodstream in a controlled, sustained manner. Columbia sold U.S. rights to STRIANT to Actient Pharmaceuticals LLC in April 2011. The Urology Company markets STRIANT in the United Kingdom and certain other European countries. Invaron Pharmaceuticals holds license and marketing rights to STRIANT in Canada. Other regions are available for license. For additional information on STRIANT:
STRIANT® is a registered trademark of Actient Pharmaceuticals LLC in the U.S. STRIANT® SR is a registered trademark of The Urology Company in the United Kingdom and the E.U. STRIANT® is a registered trademark of Invaron Pharmaceuticals in Canada.
